• Home
  •  / Cellestia Biotech

Cellestia Biotech

OverviewSuggest Edit

Cellestia Biotech is a biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Its pipeline is supported by the research in the field of oncology and cancer stem cells biology. Cellestia is engaged in the development of mechanisms-based targeted therapeutics to address unmet medical needs, with an emphasis on oncology and immunological disorders. Its anti-cancer CB-103 is a novel, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.
TypePrivate
Founded2014
HQBasel, CHMap
Websitecellestia.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2017)6
Cybersecurity ratingAMore

Key People/Management at Cellestia Biotech

Michael Bauer

Michael Bauer

CEO
Maximilien Murone

Maximilien Murone

COO
Gaudenz von Capeller

Gaudenz von Capeller

CFO
Raj Lehal

Raj Lehal

Co-Founder, Cellestia Biotech S.A.
Florian Vogl

Florian Vogl

Chief Medical Officer
Doriano Fabbro

Doriano Fabbro

Senior VP Research
Show more

Cellestia Biotech Office Locations

Cellestia Biotech has offices in Basel and Epalinges
Basel, CH (HQ)
60C Hochbergerstrasse
Epalinges, CH
Route de la Corniche 3
Show all (2)

Cellestia Biotech Financials and Metrics

Summary Metrics

Founding Date

2014

Cellestia Biotech total Funding

$48.6 m

Cellestia Biotech latest funding size

$20.39 m

Time since last funding

a year ago

Cellestia Biotech investors

Partners Investment, Go Beyond Investing, PPF Group, Trudi Haemmerli, Foundation for Technological Innovation (FIT), FC Capital, ETP Ventures
Cellestia Biotech's latest funding round in December 2019 was reported to be $20.4 m. In total, Cellestia Biotech has raised $48.6 m
Show all financial metrics

Cellestia Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Cellestia Biotech Online and Social Media Presence

Cellestia Biotech's Trends

Embed Graph

Cellestia Biotech Blogs

March 03, 2021

Cellestia’s article in Nature Biopharma Deal Makers

Cellestia’s article  “Gene transcription factor inhibitors: a novel class of therapeutics modulating gene expression” has been published in Nature Bipharma Deal Makers. To read the article please click here. The post Cellestia’s article in Nature Biopharma Deal Makers appeared first on .
February 08, 2021

Cellestia has received the Innosuisse Certificate

Cellestia has been granted the Innosuisse Certificate. This shows that Cellestia has all the necessary key assets to continue on its successful track. The post Cellestia has received the Innosuisse Certificate appeared first on .
December 07, 2020

Cellestia launches a new drug discovery program to target Transcription Factors

Cellestia initiates a new drug discovery program focused on Transcription Factors which addresses unmet medical need in cancer, autoimmune and inflammatory disorders. The program is launched in collaboration with Prof. Vincent Zoete from the Department of Oncology UNIL CHUV, Ludwig Institute for Can…
October 29, 2020

Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences”

Cellestia article “Notch Inhibition in Cancer: Challenges and Opportunities” has been published in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences” To read the article click here The post Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Scienc…
September 22, 2020

Cellestia presented promising clinical data of its lead compound CB-103 at ESMO 2020

Cellestia Biotech AG presented the first clinical data of its lead compound CB-103 at the virtual congress of the European Society for Medical Oncology (ESMO). To read Cellestia’s press release click here. Esmo 2020 Cellestia Poster   The post Cellestia presented promising clinical data of its lead …

 Cellestia Biotech Frequently Asked Questions

  • When was Cellestia Biotech founded?

    Cellestia Biotech was founded in 2014.

  • Who are Cellestia Biotech key executives?

    Cellestia Biotech's key executives are Michael Bauer, Maximilien Murone and Gaudenz von Capeller.

  • How many employees does Cellestia Biotech have?

    Cellestia Biotech has 6 employees.

  • Who are Cellestia Biotech competitors?

    Competitors of Cellestia Biotech include Abiogen Pharma, Macopharma and Heron Therapeutics.

  • Where is Cellestia Biotech headquarters?

    Cellestia Biotech headquarters is located at 60C Hochbergerstrasse, Basel.

  • Where are Cellestia Biotech offices?

    Cellestia Biotech has offices in Basel and Epalinges.

  • How many offices does Cellestia Biotech have?

    Cellestia Biotech has 2 offices.